Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18844417 | 1.00 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7656368 | 1.00 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7663519 | 0.97 | CCR3 (0.95) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7663513 | 0.97 | CCR3 (0.95) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7658588 | 0.94 | CCR3 (0.90) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7658592 | 0.94 | CCR3 (0.90) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6774786 | 0.94 | CCR3 (0.88) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7662121 | 0.92 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7662128 | 0.92 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18844269 | 0.92 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | claimed |
| EP-1140833-A1 | 2-SUBSTITUTED-4-NITROGEN HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035876-A1 | 2-SUBSTITUTED-4-NITROGEN HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-1140833-A1 | 2-SUBSTITUTED-4-NITROGEN HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035876-A1 | 2-SUBSTITUTED-4-NITROGEN HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |